Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
4 Bladder cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
5 Bladder cancer 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
6 Bladder cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
7 Calcium signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
8 Calcium signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
9 Calcium signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
10 Chemical carcinogenesis - reactive oxygen species 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
11 Chemical carcinogenesis - reactive oxygen species 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
12 Chemical carcinogenesis - reactive oxygen species 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
13 Chemical carcinogenesis - receptor activation 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
14 Chemical carcinogenesis - receptor activation 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
15 Chemical carcinogenesis - receptor activation 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
16 Fluid shear stress and atherosclerosis 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
17 Fluid shear stress and atherosclerosis 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
18 Fluid shear stress and atherosclerosis 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
19 Focal adhesion 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
20 Focal adhesion 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
21 Focal adhesion 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
22 HIF-1 signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
23 HIF-1 signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
24 HIF-1 signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
25 Human cytomegalovirus infection 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
26 Human cytomegalovirus infection 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
27 Human cytomegalovirus infection 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
28 Human papillomavirus infection 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
29 Human papillomavirus infection 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
30 Human papillomavirus infection 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
31 Integrin signaling 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
32 Integrin signaling 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
33 Integrin signaling 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
34 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
35 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
36 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
37 MAPK signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
38 MAPK signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
39 MAPK signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
40 MicroRNAs in cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
41 MicroRNAs in cancer 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
42 MicroRNAs in cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
43 Pancreatic cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
44 Pancreatic cancer 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
45 Pancreatic cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
46 Pathways in cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
47 Pathways in cancer 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
48 Pathways in cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
49 PI3K-Akt signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
50 PI3K-Akt signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
51 PI3K-Akt signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
52 Proteoglycans in cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
53 Proteoglycans in cancer 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
54 Proteoglycans in cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
55 Rap1 signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
56 Rap1 signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
57 Rap1 signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
58 Ras signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
59 Ras signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
60 Ras signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
61 Relaxin signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
62 Relaxin signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
63 Relaxin signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
64 Renal cell carcinoma 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
65 Renal cell carcinoma 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
66 Renal cell carcinoma 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
67 Rheumatoid arthritis 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
68 Rheumatoid arthritis 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
69 Rheumatoid arthritis 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
70 VEGF signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
71 VEGF signaling pathway 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
72 VEGF signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬

Back to top